Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

COVID 19 Clinical Trial

— LILIADE-COVID  

Official title:

Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04357444
• Other study ID #: APHP200406
• Secondary ID: 2020-001571-32
• Status: Completed
• Phase: Phase 2
• Start date: October 23, 2020
• Est. completion date: April 5, 2021

Study information

• Verified date: April 2021
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose is to demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related ARDS.

Description:

About 25% of hospitalized patients with SARS-CoV2 infection presented life-threatening respiratory conditions. Of these, 60% met ARDS criteria leading to death in 25% to 63% of the cases. SARS-CoV2-related ARDS is caused by a massive inflammatory cell infiltration leading to dysregulated cytokine/chemokine responses with lung immunopathological changes. To date, there is no treatment available.

Regulatory T cells (Treg) are a subpopulation of CD4+ T cells playing a crucial role in the control of immune responses, in part by preventing excessive inflammation. Depletion of Treg cells in models of lung infection or after berylium exposure exacerbated lung inflammation. In contrast, a beneficial role for Treg during early ARDS and its resolution has been observed.

Low-dose interleukin 2 (Ld-IL2) is the first therapy driving Treg-specific expansion and activation. Ld-IL2 was successfully tested in a wide range of preclinical models of inflammatory diseases, including beryllium-induced lung inflammation. Moreover, Ld-IL2 has been shown to be safe and free of serious adverse events when administered in patients with various autoimmune diseases. Importantly, in our previous work, we observed only very low concentrations of IL-2 in the blood (0.1 pg/mL [0.0-2.0]) as well as in the BAL supernatant (0.8 pg/mL [0.4-1.3]) collected from patients during the early phase of ARDS, suggesting that additional IL-2 could be beneficial for Treg expansion/activation.

Our objective is therefore to investigate the therapeutic benefit of Ld-IL2 as a Treg inducer for controlling SARS-CoV2-related ARDS.

After admission of patients to the intensive care unit at one of the recruiting centers, the eligibility criteria will be checked by the investigating physician and participation in the study will be proposed to the patient or parent/family member/trusted person. If the patient is unable to consent and there is no parent/family member/trusted person, the patient may be included in the emergency procedure.

After inclusion (J0), the patient will be randomized to one of the 2 treatment arms (low dose IL-2 or placebo).

The experimental treatment will be daily administered to the patient from D1 to D10.

The patient will be monitored daily until D28 during hospitalization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 5, 2021
• Est. primary completion date: November 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, age = 18 years

• Laboratory (RT-PCR) confirmed infection with SARS-CoV2

• Patient is either under invasive or non-invasive mechanical ventilation (including high flow nasal oxygen therapy).

• Diagnosis of ARDS according to the Berlin definition of ARDS

• Onset of ARDS <96 hours

• Patient with French Social Security System

• A written informed consent by the designated substitute decision maker, if present. In the event of absence, the patient can be included by investigator's decision alone.

Exclusion Criteria:

• Previous history of ARDS in the last month

• Chronic respiratory diseases requiring long-term oxygen therapy and/or long-term respiratory assistance

• History of organ allograft.

• Active cancer

• Liver cirrhosis with basal Child and Pugh of C

• Pulmonary fibrosis

• Patient with end-of-life decision

• Patient not expected to survive for 24 hours

• Woman known to be pregnant, lactating or with a positive (urine or serum test) or indeterminate (serum test) pregnancy test

• Patient already enrolled in another interventional pharmacotherapy protocol on COVID-19

• Patient with known hypersensitivity to natural or recombinant Interleukin-2 or to any of the excipients

• Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 1.5x109/L, AST or ALT greater than 5 x ULN, platelets <50,000 per mm3

• Use of chronic oral corticosteroids > 10 mg prednisone equivalent a day for a non-COVID-19-related condition

• Current uncontrolled autoimmune disease

• Patients with uncontrolled suspected or known active systemic bacterial or fungal infections

• Patient with severe, uncontrolled pre-existing (chronic) organ failure (myocardial, hepatic or renal)

• Vaccination with live attenuated vaccines in the month preceding the inclusion

• Patient with burns to = 15% of their total body surface area

• Patient receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support

• Patient under legal protection (protection of the court, or in curatorship or guardianship).

Related Conditions & MeSH terms

• Acute Lung Injury
• COVID 19
• COVID-19
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

Intervention

Drug:
• 1: ILT101
Subcutaneous injections, once-daily administration for 10 consecutive days.
• 2: Placebo Comparator
placebo in Subcutaneous route

Locations

Country	Name	City	State
France	Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Iltoo Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The PaO2/FiO2 ratio at D11		at Day11
Secondary	Changes in Tregs between Baseline and Day 7 (expressed in %)		at Day0 and Day7
Secondary	Number of days alive with oxygen therapy within 28 days		at Day28
Secondary	Maximal oxygen rate within 28 days		at Day28
Secondary	Number of days alive free of invasive or non-invasive ventilation within 28 days		At Day28
Secondary	Number of days alive outside ICU within 28 days		at Day28
Secondary	Number of days alive outside hospital within 28 days		at Day28
Secondary	Time (in days) from randomization to death		through study completion at day 28
Secondary	Mortality rate at D28		at Day28
Secondary	Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)		at Day0 and Day7 or at the time of discharge
Secondary	Use of antibiotics for respiratory (proved or suspected) infection within 28 days		at Day28
Secondary	Number of prone positioning sessions		throughout the follow up period at day 28
Secondary	Changes in Tregs during the different visits between baseline and day 28		at Day0, 5, 7, 11, 14 and Day28
Secondary	Cytokines analysis on plasma samples at Day 0, 7 and 14	To evaluate selected immune and inflammatory markers: Serum concentrations of cytokines and soluble factors related to the immune response and inflammatory processes will be evaluated and compare to baseline by multiplex immunoprofiling to analyse a larger number of molecules including at least IFNa2, IFN?, IL-1a, IL-1ß, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, TNFa, TNFß, VEGF-A, TGF-beta, S-RAGE, SP-A, SP-D, Angiopoétine 1 and KGF.	at Day 0, 7 and 14
Secondary	Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.		at Day0, 5, 7, 11, 14 and Day28
Secondary	Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.		at Day0, 5, 7, 11, 14 and Day28
Secondary	Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14	Cellular components will be analysed by flow cytometry covering (i) most of the innate and adaptive immune cells including Tregs, T helper cell subsets including follicular helper cells, B cell subsets, NK cell subsets, (ii) the associated relevant markers of activation/function/differentiation, tissue migration, as well as (iii) unconventional lymphoid cells (NKT/MAIT, innate lymphoid cells), myeloid-derived suppressor cells, classical and non-classical monocytes and dendritic cells (mDC1/2, pDC).	at Day0, 7 and Day14
Secondary	T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline		at Day0, 7 and Day14
Secondary	T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline		at Day0, 7 and Day14
Secondary	Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.		at Day0, 7 and Day14